Bacopa (Bacopa monnieri)
1. Identity: Botanical Classification, Names, and Natural Source
Bacopa monnieri (L.) Wettst. belongs to the family Scrophulariaceae and is an extensively used herb in Ayurveda. More recent taxonomic revisions place it within the family Plantaginaceae. It is popularly known as Brahmi and is widely considered the water hyssop or Indian pennywort. Additional synonyms include the binomial Bacopa monniera (an alternate spelling found in older literature), along with common names such as herb of grace and Andri.
Bacopa monnieri is a medicinal creeping perennial with small oblong leaves and white to purple flowers, frequently used in Ayurvedic medicine. It is a nootropic herb distributed throughout the wetlands of the tropics and subtropics. The plant thrives in damp, marshy environments and is found across South Asia, Southeast Asia, and parts of the Americas and Australia. It is an annual creeping plant found in wet, damp, and marshy areas, and the leaves and stem of the plant are used for medicinal purposes traditionally.
Common Preparations and Dosage Forms
Bacopa monnieri-based formulations used in traditional Ayurveda include Brahmi ghrita, Brahmi rasayana, Brahmi vati, and Saraswata ghrita. Modern commercial preparations include standardized dry extracts in capsule or tablet form, powders, and syrups. Bacopa monnieri is available in multiple over-the-counter herbal products. The typical dose reported for the extract is 300 to 600 mg daily, described as equivalent to 5 to 10 grams of the dried herb.
Standardization of commercial extracts is most commonly expressed in terms of total bacoside content. Bacoside A was identified as a mixture of four saponins — bacoside A3, bacopaside II, bacopasaponin C, and the jujubogenin isomer of the latter — and these major saponins now form part of analytical monographs in many Pharmacopoeias. The proprietary extract designated CDRI 08 (also marketed as KeenMind) has been used across a number of clinical trials.
2. Traditional and Historical Use
Its use has been documented in the Ayurvedic text Caraka Samhita as a treatment for various mental conditions. Ayurvedic medicine describes Bacopa as a "medhya rasayana," meaning a class of herbs believed to improve mental health, memory, and intellect and promote rejuvenation and longevity.
In Ayurveda, it is classified as a Rasayana (rejuvenation) herb and is projected to promote mental and physical health, rejuvenate the body in debilitated conditions, and increase longevity. Brahmi has been applied in Ayurveda since many generations as a nerve tonic and treatment of neurological disease. In the 16th century, Bacopa is recommended in the Ayurvedic text Caraka Samhita for the treatment of a wide range of mental illnesses.
References to Bacopa monnieri date back over 3,000 years in classical Ayurvedic texts like the Charaka Samhita and Sushruta Samhita, where Brahmi was praised as a "medhya rasayana." Ancient practitioners in Vedic times recommended Brahmi for students preparing for exams, scholars reciting long verses, and monks engaged in deep meditation.
The herb was used by ancient Vedic scholars due to its pharmacological effect, especially as a nerve tonic and nootropic booster. Since at least the sixth century A.D., bacopa has been used in Ayurvedic medicine as a diuretic and tonic for the nervous system as well as the heart.
Traditional preparations were diverse. In Kerala's traditional Ayurveda, Brahmi leaves are crushed into a paste for topical relief of ulcers and minor wounds, while decoctions or ghrita (ghee-based formulations) target nervous exhaustion and anxiety. Across Southeast Asia and in traditional Unani medicine of Persia, Bacopa monnieri was similarly valued for boosting memory and alleviating mental fatigue. The herb was also administered as a syrup, infused in warm milk or honey, and as a medicated oil for topical application.
Traditional Ayurvedic indications extended beyond cognition. Animal and human clinical studies support the traditional use of Bacopa monnieri for other indications, including epilepsy, bronchitis, asthma, gastrointestinal disorders, and hypothyroidism.
3. Key Constituents and Active Compounds
Eight decades of phytochemical studies have resulted in the isolation of 98 secondary metabolites from Bacopa monnieri, comprising dammarane-type triterpenoid saponins (34), pentacyclic triterpenes (6), phenylethyl glycosides (12), phenylpropanoid glycosides (2), cucurbitacins (7), steroids (8), flavonoids (6), alkaloids (3), and other miscellaneous compounds (20).
The best characterized phytochemicals in Bacopa monnieri are dammarane-type triterpenoid saponins known as bacosides, with jujubogenin or pseudo-jujubogenin moieties as aglycone units. Bacosides comprise a family of 12 known analogs. Other saponins called bacopasides I–XII have been identified. The alkaloids brahmine, nicotine, and herpestine have been catalogued, along with D-mannitol, apigenin, hersaponin, monnierasides I–III, cucurbitacin, and plantainoside B.
The leaves contain triterpenoid saponins (Bacoside A, Bacoside B, bacopasaponins, D-mannitol, acid A, monnieri), alkaloids (brahmine, nicotine, herpestine, hydrocotyline), flavonoids (luteolin, apigenin), glycosides, phytochemicals (betulinic acid, betulic acid, wogonin, oroxindin, stigmasterol, beta-sitosterol), sapogenins (jujubacogenin, pseudojujubacogenin), and other compounds including Brahmic acid, brahamoside, brahminoside, and isobrahmic acid. The saponins are believed to be responsible for most of the pharmacological actions.
The precise identity and composition of "bacoside A" has been clarified in modern analytical chemistry. The active constituents were putatively identified as "bacosides A and B" in older publications; subsequently "bacoside A" was identified as a mixture of four saponins — bacoside A3, bacopaside II, bacopasaponin C, and the jujubogenin isomer of the latter. The identity of "bacoside B" has remained more controversial in the scientific literature.
Bacoside A can constitute up to 8% of the dry leaves by weight when fresh. Other bacosides are present in lesser amounts, ranging from approximately 1.43% (bacopaside-I) to 2.74% (bacopaside-II). HPLC-based studies have quantified individual components of bacoside A: bacoside A3 ranged from 0.14% to 0.85%, and bacopaside II from 0.12% to 0.69%, values that reflect regional variation.
Bacopa monnieri plant is rich in clinically critical secondary metabolites such as saponins, alcohols, steroids, alkaloids, glycosides, sterol glycosides, phenylethanoid glycosides, sugars, amino acids, flavonoids, and cucurbitacins. Specific compounds identified in extracts include brahmine, hydrocotyline, nicotine, herpestine, D-mannitol, stigmasterol, and several amino acids including glutamic acid, aspartic acid, alanine, and serine.
Flavonoids present in Bacopa monnieri such as luteolin and apigenin are reported as potent vasodilators. The primary alkaloids found in Bacopa monnieri include brahmine, which is believed to contribute to its neuroprotective effects.
4. Mechanisms of Action
The biological activity of Bacopa monnieri is thought to be multifactorial. Current evidence suggests Bacopa monnieri acts via the following mechanisms: anti-oxidant neuroprotection (via redox and enzyme induction), acetylcholinesterase inhibition and/or choline acetyltransferase activation, β-amyloid reduction, increased cerebral blood flow, and neurotransmitter modulation involving acetylcholine (ACh), 5-hydroxytryptamine (5-HT), and dopamine (DA).
Antioxidant Neuroprotection
Based on animal studies, the bacosides appear to have antioxidant activity in areas of the brain including the hippocampus, frontal cortex, and striatum. Bacopa enhances certain enzymes including superoxide dismutase (SOD) and catalase involved in the generation and scavenging of reactive oxygen species (ROS) such as free radicals in the brain, possibly by NRF2 activation. Neurons treated with the extract exhibited lower levels of reactive oxygen species, suggesting a reduction in intracellular oxidative stress and an extension of neuronal lifespan. The extract also demonstrated antioxidant properties and inhibited lipid peroxidation.
Cholinergic Modulation
In vitro biochemical studies have demonstrated dose-dependent suppression of acetylcholine hydrolysis by Bacopa monnieri phytocompounds, suggesting they reduce AChE catalytic activity. This inhibition may enhance synaptic cleft acetylcholine levels, improving cholinergic dysfunction associated with neurodegenerative disease. These substances may increase cholinergic neurotransmission by suppressing AChE.
Neurotransmitter Modulation
Bacopa primarily either acts via antioxidant mechanisms (neuroprotection) or alters different neurotransmitters — serotonin (5-HT), dopamine (DA), acetylcholine (ACh), and γ-aminobutyric acid (GABA) — to execute its pharmacological effects. Among these, 5-HT has been shown to fine-tune neural plasticity, which is a substrate for memory formation.
β-Amyloid Reduction
Methanol extracts have shown anti-amyloidogenic potential by significantly affecting the dissociation of amyloid protein aggregates. A study on cultured rat cells confirmed these findings, showing a reduction in beta-amyloid deposition in the brain. However, in silico and in vivo studies indicate anti-amyloidogenic and antioxidant effects, but clinical studies confirming these mechanisms in Alzheimer's patients are lacking.
Neurotrophic and Synaptic Effects
The therapeutic effects of bacosides demonstrated in preclinical and in vitro studies include enhancement of neurotransmission, potentiation of synaptic activity, and repair of damaged neurons by upregulating neuronal synthesis and kinase activity. The triterpenoid saponins and their bacosides were found to be responsible for Bacopa's ability to enhance nerve impulse transmission.
5. Scientific Evidence by Area of Use
5.1 Cognitive Performance and Memory in Healthy Adults
The most extensively studied indication for Bacopa monnieri in humans is cognitive enhancement — particularly memory — in adults without dementia. Multiple randomized controlled trials (RCTs) and systematic reviews have examined this question.
A pivotal systematic review by Pase et al. (2012), published in the Journal of Alternative and Complementary Medicine, surveyed the available RCT evidence. Trials were all conducted over 12 weeks. Across trials, three different Bacopa extracts were used at dosages of 300–450 mg extract per day. Across studies, Bacopa improved performance on 9 of 17 tests in the domain of memory free recall. There was little evidence of enhancement in any other cognitive domains. The authors concluded there is some evidence to suggest that Bacopa improves memory free recall, with evidence for enhancement in other cognitive abilities currently lacking, perhaps due to inconsistent measures employed by studies.
A subsequent formal meta-analysis (Kongkeaw et al., 2014), published in the Journal of Ethnopharmacology, examined only placebo-controlled RCTs using chronic dosing of ≥12 weeks. The systematic review and meta-analysis of randomized controlled trials demonstrated that Bacopa monnieri extract has the potential to improve cognitive performance, particularly speed of attention by reducing choice reaction time. Randomized, placebo-controlled human intervention trials on chronic ≥12 weeks dosing of standardized extracts of Bacopa monnieri without any co-medication were included.
One notable RCT with a population of elderly adults without dementia was conducted by Calabrese et al. Fifty-four participants aged 65 or older (mean age 73.5 years), without clinical signs of dementia, were recruited and randomized to Bacopa or placebo; 48 completed the study with 24 in each group. Participants received standardized Bacopa monnieri extract at 300 mg/day or a similar placebo tablet orally for 12 weeks. The primary outcome was the delayed recall score from the Rey Auditory Verbal Learning Test (AVLT). Other cognitive measures included the Stroop Task, the Divided Attention Task (DAT), and the Wechsler Adult Intelligence Scale letter-digit test of immediate working memory. Affective measures included the State-Trait Anxiety Inventory and the Center for Epidemiologic Studies Depression scale. Controlling for baseline cognitive deficit, Bacopa participants had enhanced AVLT delayed word recall memory scores relative to placebo, providing evidence that Bacopa monnieri has potential for safely enhancing cognitive performance in aging.
One study demonstrated that Bacopa monnieri significantly improved speed of visual information processing measured by an inspection time task, learning rate and memory consolidation measured by the Auditory Verbal Learning Test (AVLT), and state anxiety compared to placebo, with maximal effects evident after 12 weeks. These findings suggest that Bacopa monnieri may improve higher-order cognitive processes critically dependent on the input of information from the environment, such as learning and memory.
Limitations of the cognitive evidence base: Despite promising results obtained in numerous studies, there are important limitations that need to be taken into account when interpreting results. Most of the available studies are in silico analyses, in vitro experiments, or animal model studies. Although they point to potential mechanisms of action and beneficial effects on neuroprotective parameters, a systematic assessment of the quality of this evidence is lacking. In many cases, studies are characterized by small samples, lack of blinding, and short durations, limiting the generalizability of the results to the human population. Translating the results of preclinical studies into clinical effects remains a major challenge.
5.2 Cognitive Performance in Older Adults and Age-Associated Memory Impairment
Several RCTs have specifically targeted older adults with age-associated memory impairment. The systematic review evidence across populations identified six systematic reviews or meta-analyses on up to 11 clinical trials assessing the cognitive effects of Bacopa. The Alzheimer's Drug Discovery Foundation (ADDF) Cognitive Vitality review notes that multiple preclinical studies in animals or test tubes have established a biological rationale for protective properties, but these effects have not been confirmed in humans.
In a key elderly cohort study, Bacopa significantly improved memory acquisition and retention in healthy older Australians, which concurs with previous findings and traditional use.
5.3 Alzheimer's Disease and Dementia
Bacopa monnieri has been investigated in patients with Alzheimer's disease (AD), though this evidence base is considerably weaker than that for healthy adult cognition. A comprehensive 2022 systematic review (Basheer et al.) searched multiple databases for RCTs in patients with AD and mild cognitive impairment (MCI). The comprehensive search yielded 5 eligible studies; 3 used Bacopa monnieri in combination with herbal extracts while the remaining 2 used Bacopa monnieri extracts only. Two studies compared Bacopa monnieri with donepezil while the others used a placebo as the control. There was considerable variation in the Bacopa monnieri dose used, ranging between 125 mg to 500 mg twice daily, and heterogeneity in treatment duration, follow-up, and outcomes.
Using the Cochrane risk-of-bias tool, all 5 studies were judged to be at high risk of bias. While all studies reported a statistically significant difference between Bacopa monnieri and the comparator in at least one outcome, the overall quality of evidence for the Alzheimer's Disease Assessment Scale-Cognitive Subscale, Postgraduate Institute Memory Scale, Mini-Mental State Examination, and Wechsler Memory Scale was rated as very low, due to downgrading for high risk of bias and impreciseness caused by small sample sizes and wide confidence intervals.
There was no difference between Bacopa monnieri and the placebo or donepezil in the treatment of Alzheimer disease based on very low certainty evidence.
One phase 2b RCT (Prabhakar et al., 2020) was a 52-week, randomized, double-blind, parallel-group, phase-2 single-center clinical trial comparing the efficacy and safety of Bacopa monnieri 300 mg once daily and donepezil 10 mg once daily for 12 months in 48 patients with AD and MCI-AD, including cognitive and quality-of-life outcomes.
Bacopa has not been shown to be effective for any disease or medical symptom in adequately controlled, prospective trials in humans, and bacopa is not approved in the United States as therapy of any medical condition.
5.4 ADHD and Behavioral Outcomes in Children and Adolescents
Research has examined Bacopa monnieri's potential in attention-deficit/hyperactivity disorder (ADHD) and related behavioral outcomes in younger populations. A systematic review of Bacopa monnieri in child and adolescent populations (Kean et al., 2016, published in Phytotherapy Research) identified relevant trials. Two studies reported improvements in hyperactivity and attention in children diagnosed with ADHD; significant outcomes demonstrated small to medium effect sizes (mean d = 0.42); and Bacopa monnieri was well tolerated with only 2.3% of all participants reporting mild side-effects.
In one study, children were given a dose of 225 mg per day for 6 months. The dosage proved not only safe but also effective in eliminating ADHD symptoms in children within a certain age range.
The BACHI study (Bachmann, 2015) was designed as the first 16-week, randomized, placebo-controlled, double-blind, parallel-groups trial examining the efficacy and safety of CDRI 08 in male children aged 6–14 years with high levels of inattention and hyperactivity. The primary outcome variable was the level of hyperactivity and inattention measured by the Conners' Parent Rating Scale (CPRS). Secondary outcome variables included cognition, mood, sleep, and EEG.
A systematic analysis indicates that the use of Bacopa monnieri supplements is correlated with a reduction in hyperactivity, augmentation of memory retention, amplified concentration, and an absence of detrimental side effects. However, this evidence base remains limited by small trial sizes and the need for larger, more rigorous studies. Standardized trial designs in clinical pediatric populations are essential to ensure the outcomes reported are reliable and valid.
5.5 Anxiety and Stress
Both animal and clinical research data support the traditional Ayurvedic use of Bacopa monnieri for stress and anxiety. A study in a rat model of anxiety demonstrated that a Bacopa extract exerted anxiolytic activity comparable to lorazepam, a widely used benzodiazepine anxiolytic drug.
In human clinical work, anxiety reduction has been a secondary outcome in several cognitive trials. A clinical trial of 35 patients with diagnosed anxiety neurosis demonstrated that administration of Brahmi syrup (equivalent to 12 g dry crude extract of Bacopa) resulted in a significant decrease in anxiety symptoms, level of anxiety, level of disability, and mental fatigue, and exhibited a considerable increase in immediate memory span.
Clinical studies have demonstrated that daily doses of 300 to 600 mg of Bacopa monnieri extract standardized for the amount of bacosides, equivalent to 5 to 10 g of the dried herb, can enhance cognitive function and alleviate symptoms of anxiety and depression. However, anxiety and depression outcomes have largely been secondary endpoints in trials primarily designed to measure cognition, limiting the strength of conclusions in this area.
5.6 Neuroprotective Effects: Parkinson's Disease and Epilepsy
There is evidence for potential attenuation of dementia, Parkinson's disease, and epilepsy. However, this evidence is primarily drawn from animal and in vitro experiments. The plant has been studied for its potential in treating Alzheimer's disease, Parkinson's disease, ADHD, and depression. Animal studies have shown promising results in reducing symptoms and protecting against neurodegeneration. Controlled human clinical trials in Parkinson's disease and epilepsy are lacking.
6. Body Systems and Health Areas Associated with Bacopa
- Central Nervous System / Cognition: Memory, learning, attention, and processing speed; the best-studied area in humans. Bacopa monnieri has been extensively studied for its bioactive constituents responsible for memory-enhancing effects.
- Neuropsychiatric: Anxiety, depression, and mood. Bacopa's pharmacological activities include antiepileptic, anxiolytic, antidepressant, sedative, antioxidant, and anti-inflammatory activities.
- Neurodegenerative: Alzheimer's disease and related dementias — investigated but supported only by very low-certainty evidence in humans.
- Pediatric Behavioral: ADHD-associated inattention and hyperactivity — modest clinical evidence.
- Gastrointestinal: Antiulcer and gastroprotective effects documented in preclinical studies. Bacopa possesses gastrointestinal pharmacological activities alongside antioxidant, endocrine, antimicrobial, and anti-inflammatory properties.
- Antioxidant / Anti-inflammatory: Documented in multiple preclinical models; human clinical evidence is limited. Extracts isolated from Bacopa monnieri such as flavonoids, saponins, and triterpenes prevent oxidative and mitochondrial/ER stress.
- Endocrine: Thyroid hormone interactions have been noted in animal studies (see Safety section).
7. Dosages Reported in Studies
Dosage information below reflects only what has been reported in cited sources and should not be interpreted as dosing recommendations.
- Trials in healthy adult populations were all conducted over 12 weeks, using three different Bacopa extracts at dosages of 300–450 mg extract per day.
- One 12-week RCT in elderly participants used standardized Bacopa monnieri extract at 300 mg/day.
- Clinical studies have reported daily doses of 300 to 600 mg of standardized extract for effects on cognitive function and anxiety symptoms.
- A 52-week phase 2b RCT in Alzheimer's disease and MCI used Bacopa monnieri at 300 mg once daily.
- Doses in the Alzheimer's disease systematic review ranged between 125 mg to 500 mg twice daily across different trials.
- In a pediatric ADHD study, children were given a dose of 225 mg per day for 6 months.
- A 30-day clinical toxicity study administered 300 mg and 450 mg tablets to participants, with each dose consumed for 15 days.
- The standardized extract equivalent of 300–600 mg per day is described as roughly equivalent to 5 to 10 grams of the dried herb.
- Cognitive effects are typically observed after 12 weeks of consistent supplementation.
8. Safety Considerations and Drug Interactions
General Safety Profile
Bacopa monnieri has been found to be generally non-toxic, with no serious side effects reported in reviewed studies. Bacopa has only minor and usually short-lived side effects, which may include abdominal pain, nausea, diarrhea, flatulence, dry mouth, headache, dizziness, insomnia, and rash. The overall rate of adverse events in bacopa-treated subjects has usually been similar to that in placebo controls.
The most common side effects are gastrointestinal, including increased stool frequency, nausea, and abdominal cramps. In some cases, gastrointestinal disorders in the form of diarrhea have appeared.
Hepatotoxicity
There is no evidence to indicate that Bacopa monnieri causes liver injury, despite the fact that it has multiple ingredients including triterpenoid bacopa saponins and saponin glycosides. The NIH LiverTox database assigns it a Likelihood Score of E (unlikely cause of clinically apparent liver injury).
Cholinergic Effects and Drug Interactions
As a result of its cholinergic activity, Bacopa could counteract the effects of anticholinergic drugs and may worsen bradycardia and exacerbate conditions such as gastrointestinal obstruction, peptic ulcer disease, pulmonary conditions such as asthma, and chronic obstructive pulmonary disease or urogenital tract obstruction.
Cytochrome P450 Interactions
Bacopa has been shown to inhibit human cytochrome P450 enzymes, which could contribute to herb-drug interactions when co-administered orally with medications metabolized by CYP1A2, CYP2C9, CYP3A4, and CYP2C19. This is a particularly important consideration for patients taking drugs with narrow therapeutic windows that rely on these metabolic pathways.
Thyroid Hormone Interactions
Animal research suggests Bacopa may increase thyroxine levels (T4) in mice by about 40%. It should be used cautiously (or avoided) in those with a thyroid condition or who take thyroid hormone medications. Bacopa monnieri has been found to be generally non-toxic; however, interactions with certain medications and contraindications in conditions like hyperthyroidism should be considered.
Reproductive Effects
A study assessed the effect of Bacopa monnieri extract on mouse fecundity. Bacopa monnieri was found to have the ability to induce reversible suppression of spermatogenesis and fertility in mice. However, it does not affect libido or cause toxic effects.
Pregnancy and Breastfeeding
Further research is needed to determine optimal dosages and ensure safety, especially for pregnant and breastfeeding women. Controlled human data in these populations are lacking.
Safety Data Reporting Limitations
Safety data is often overlooked or under-reported in trials involving Bacopa monnieri. In a review by Kean et al. (2017), 44% (4 out of 9 studies) of the included studies did not report any safety outcomes and tolerability data.
Regulatory Status
In 2019, the FDA issued warning letters to manufacturers of dietary supplements containing Bacopa monnieri that advertised health claims for treating or preventing stomach disease, Alzheimer's disease, hypoglycemia, blood pressure, and anxiety, stating these claims were unproven and illegal. The FDA stated that no Bacopa monnieri products have been approved for medical purposes.
References
Go back